Another reason is that some PAD (e.g., STAT5b GOF, KIT, and ADGRE2 gene mutations) could have a prominent clinical and laboratory feature of hypereosinophilia or aberrant mast cell activation, which do not fit with the definition of “hyper‐IgE syndromes” in the IUIS classification. Here, ADGRE2 is linked to peripheral arterial disease.